Roche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of “Hold” from Analysts

Roche Holding AG (OTCMKTS:RHHBY) has earned an average rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company.

Several research firms have issued reports on RHHBY. Morgan Stanley began coverage on Roche in a report on Wednesday. They set an “equal weight” rating on the stock. Sanford C. Bernstein upgraded Roche to a “strong-buy” rating in a report on Thursday, January 30th.

Institutional Investors Weigh In On Roche

A number of large investors have recently added to or reduced their stakes in RHHBY. Brooklyn Investment Group bought a new stake in shares of Roche in the third quarter valued at approximately $40,000. AlphaMark Advisors LLC bought a new stake in shares of Roche in the third quarter valued at approximately $149,000. IHT Wealth Management LLC bought a new stake in shares of Roche in the third quarter valued at approximately $236,000. Verity Asset Management Inc. bought a new stake in shares of Roche in the third quarter valued at approximately $253,000. Finally, Canopy Partners LLC boosted its position in shares of Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock valued at $310,000 after acquiring an additional 344 shares during the period.

Roche Price Performance

OTCMKTS:RHHBY opened at $39.43 on Wednesday. The business’s 50-day moving average price is $36.70 and its 200 day moving average price is $38.31. Roche has a 52-week low of $29.20 and a 52-week high of $42.43. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.